News

The company’s latest report states that the increase in PAH treatment sales, which will occur across the seven major markets of the US, France, Germany, Italy, Spain, the

Under the bestPWS ZAF-311 double-blind, placebo-controlled phase 3 trial, the company evaluated the safety and efficacy of beloranib in patients with Prader-Willi syndrome (PWS) in a six-month randomized

Arhalofenate is a novel dual-acting product candidate for the treatment of gout that lowers serum uric acid (sUA) and reduces gout flares. It inhibits a renal uric acid

The European Commission (EC) approved Entresto in November 2015 to treat adult patients with symptomatic chronic heart failure with reduced ejection fraction (HfrEF). Entresto performs the mechanism of

EyeGate president and CEO Stephen From said: "Enrolling the first patient in our second Phase 3 trial for anterior uveitis marks an important milestone for the company as

This Phase 2B study, is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients

Designed to validate Immunovia´s blood test, IMMray PanCan-d, the study will run for three years across sites in both the US and Europe, starting in the second half

As a result, Incyte will receive a milestone payment of $35m from Lilly related to the NDA submission. If baricitinib is granted U.S. regulatory approval, Incyte will receive

Biotie is primarily focused on developing therapeutics for central nervous system disorders. The company develops products for neurodegenerative and psychiatric disorders such as Parkinson’s disease, Alzheimer’s disease and